A multicenter randomized clinical trial comparing paclitaxel-cisplatin- etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 463-470

  Mavroudis, D ^a   Papadakis, E ^b   Veslemes, M ^b   Tsiafaki, X ^c   Stavrakakis, J ^d   Kouroussis, C ^a   Kakolyris, S ^a   Bania, E ^b   Jordanoglou, J ^b   Agelidou, M ^c   Vlachonicolis, J ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c KAT HOSPITAL   (Greece)

^d Papanicolaou Research Centre of Oncology and Experimental Surgery   (Greece)

Author keywords

Cisplatin; Etoposide; Paclitaxel; Randomized trial; Small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG INFUSION; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; ETOPOSIDE; FATIGUE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PACLITAXEL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0034998541     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011131303391     Document Type: Article

References (27)

1. Ihde DC, Mulshine JL, Kramer BS et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive stage small cell lung cancer. J Clin Oncol 1996; 12: 2022-34.
2. Murray N, Coy P, Pater JL et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. J Clin Oncol 1993; 12: 336-44.
3. Bunn PA, Carney DN. Overview of chemotherapy for small cell lung cancer. Semin Oncol 1997; 24 (2, Suppl 7): 69-74.
4. Johnson D. Management of small cell lung cancer. Current state of the art. Chest 1999; 116: 525S-30S.
5. Ettinger DS, Finkelstein DM, Sarma RP et al. Phase II study of paclitaxel in patients with extensive disease small cell lung cancer: An Eastern Cooperative Group study. J Clin Oncol 1995; 13: 1430-5.
6. Kirschling RJ, Grill JP, Marks RS et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small cell lung cancer: A phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 1999; 22: 517-22.
7. Smit EF, Fokkema E, Biesma B et al. A phase II study of paclitaxel in heavily pretreated patients with small cell lung cancer. Br J Cancer 1998; 77: 347-51.
8. Bunn PA, Kelly K. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Semin Oncol 1997; 24 (4, Suppl 12): 144-8.
9. Glisson BS, Kurie JM, Fox NJ et al. Phase I II study of cisplatin, etoposide, and paclitaxel in patients with extensive small cell lung cancer. Proc Am Soc Clin Oncol 1997; 16: 455 (Abstr 1635).
10. Birch R, Weaver CH, Hainsworth JD et al. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer. Semin Oncol 1997; 24 (4, Suppl 12): 135-7.
11. Hainsworth JD, Gray JR, Stroup SL et al. Paclitaxel, carboplatin and extended-schedule etoposide in the treatment of small cell lung cancer: Comparison of sequential phase II trials using different dose intensities. J Clin Oncol 1997; 15: 3464-70.
12. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
13. Altman GD. Practical Statistics for Medical Research. London: Chapman and Hall 1991.
14. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959; 53: 457-81.
15. Cox DR. The Analysis of Binary Data. London: Methuen 1970.
16. Armitage P, Berry G. Statistical Methods in Medical Research, second edition, Boston: Blackwell Scientific Publication 1990.
17. Su GM, Davey MW, Davey RA. Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int J Cancer 1998; 76: 702-8.
18. Wolf M, Havemann K, Holle R et al. Cisplatin etoposide versus ifosfamide etoposide combination chemotherapy in small-cell lung cancer: A multicenter German randomized trial. J Clin Oncol 1987; 5: 1880-9.
19. Boni C, Cocconi G., Bisagni G et al. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial. Cancer 1989; 63: 638-42.
20. Johnson DH, Adak S, Cella DF et al. Topotecan vs. observation following cisplatin plus etoposide in extensive stage small cell lung cancer: A phase III trial of the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 2000; 19: 428a (Abstr 1886).
21. Cottin V, Arpin D, Lasset C et al. Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole. Ann Oncol 1999; 10: 809-15.
22. Klasa R, Murray N, Coldman A. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991; 9: 499-508.
23. Kelly K, Bunn PA, Lovato L et al. Final results from the Southwest Oncology group trial (SWOG) 9705: A phase II trial of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients with extensive small cell lung cancer. Proc Am Soc Clin Oncol 2000; 19: 492a (Abstr 1923).
24. Sandler A, Declerck L, Wagner H et al. A phase II study of cisplatin plus etoposide plus paclitaxel (PET) and concurrent radiation therapy for previously untreated limited stage small cell lung cancer: An Eastern Cooperative Group Trial. Proc Am Soc Clin Oncol 2000; 19: 491a (Abstr 1920).
25. Glisson BS, Kurie JM, Perez-Soler R et al. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small cell lung carcinoma. J Clin Oncol 1999; 17: 2309-13.
26. Kelly K, Pan Z, Wood ME et al. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res 1999; 5: 3419-24.
27. Levitan N, Dowlati A, Shina D et al. Multi-institutional phase I-II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 2000; 18: 1102-9.